| 【Company Research】BOC Aviation (2588 HK) – Get ready to be back on track |
| 【Sector Research】China AI surveillance – Ambarella suggested strong AI demand |
| 【Fixed Income Research】Central China – Bond price may stay subdued for now (CENCHI) |
| 【Company Research】Powerlong Commercial (9909 HK) – Remain confident in delivery and occupancy improvement despite slower-than-expected FY20 |
| 【Company Research】Shinsun Holdings (2599 HK) – The leading YRD developer with national print |
| 【Company Research】Tongcheng-Elong (780 HK) – Moving into 2021 recovery |
| 【Company Research】FIT Hon Teng (6088 HK) – Weak FY20 priced in; Belkin/PC/EV demand on track |
| 【Company Research】Xinyi Solar (968 HK) – Price war brewing |
| 【Company Research】CITIC Securities (6030 HK) – RMB 28bn A+H rights issue to beef up capital base |
| 【Company Research】Simcere Pharmaceutical Group (2096 HK) – FDA approved trilaciclib for chemotherapy-induced myelosuppression |
Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong
Telephone: （852）3900 0888 Fax:（852）3761 8788
Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
